Digest Network Come funziona
Network
/
Società
F.
Non verificato

F. Hoffmann-La Roche Ltd

Di cosa scriviamo

Annunci EconomiciFarmaceuticaPubblicità/Marketing/Media/Comunicazione

173 comunicati stampa

Guarda tutti i comunicati
27/10/2026
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
26/10/2026
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
25/10/2026
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
23/10/2026
Farmaceutica
Annunci Economici
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
21/10/2026
Farmaceutica
Pubblicità/Marketing/Media/Comunicazione
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
21/10/2026
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Roche presents new pivotal trial data across broad neuroimmunology portfolio at MSToronto2026
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
18/10/2026
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
15/10/2026
Farmaceutica
Annunci Economici
FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
10/10/2026
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
08/10/2026
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0